Cargando…
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study
BACKGROUND: Prurigo nodularis is a chronic skin disease characterised by intensely pruritic, hyperkeratotic nodules. Vixarelimab, a human monoclonal antibody, binds to the beta subunit of the oncostatin M receptor, inhibiting signalling of both interleukin 31 and oncostatin M, two cytokine pathways...
Autores principales: | Sofen, Howard, Bissonnette, Robert, Yosipovitch, Gil, Silverberg, Jonathan I., Tyring, Stephen, Loo, Wei Jing, Zook, Matthew, Lee, Mark, Zou, Liangxing, Jiang, Guang-Liang, Paolini, John F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932343/ https://www.ncbi.nlm.nih.gov/pubmed/36816342 http://dx.doi.org/10.1016/j.eclinm.2023.101826 |
Ejemplares similares
-
Immunotargets and Therapy for Prurigo Nodularis
por: Labib, Angelina, et al.
Publicado: (2022) -
Impact of Itch on Sleep Disturbance in Patients with Prurigo Nodularis
por: GWILLIM, Eran C., et al.
Publicado: (2021) -
Serum Interleukin-13 and Caspase 8 are Elevated in Prurigo Nodularis
por: JU, Teresa, et al.
Publicado: (2023) -
Dermal Periostin: A New Player in Itch of Prurigo Nodularis
por: HASHIMOTO, Takashi, et al.
Publicado: (2021) -
Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis
por: Ständer, Sonja, et al.
Publicado: (2020)